Given its involvement in pain, itching, and respiratory syndromes, TRPA1 has been pursued as a promising drug target.570 GDC-0334 is a chemical-derived drug that reduced TRPA1 agonist-induced skin blood flow, pain and pruritus in a phase I clinical trial (ClinicalTrials.gov: NCT03381144).571 GDC-0334 provides a therapeutic basis for assessing TRPA1 inhibition as a clinical treatment for asthma. This evidence concerns the gene TRPA1 and asthma.